Evidence‐based guideline: Treatment of painful diabetic neuropathy—report of the american association of neuromuscular and electrodiagnostic medicine, the american academy of neurology, and the american academy of physical medicine & rehabilitation

@article{Bril2011EvidencebasedGT,
  title={Evidence‐based guideline: Treatment of painful diabetic neuropathy—report of the american association of neuromuscular and electrodiagnostic medicine, the american academy of neurology, and the american academy of physical medicine \& rehabilitation},
  author={Vera Bril and John D. England and Gary M Franklin and Miroslav Backonja and Jeffrey A. Cohen and David R. Del Toro and Eva L. Feldman and Donald J Iverson and Bruce A. Perkins and James W. Russell and Douglas W. Zochodne},
  journal={Muscle \& Nerve},
  year={2011},
  volume={43}
}
The objective of this report was to develop a scientifically sound and clinically relevant evidence‐based guideline for the treatment of painful diabetic neuropathy (PDN). The basic question that was asked was: “What is the efficacy of a given treatment (pharmacological: anticonvulsants, antidepressants, opioids, others; non‐pharmacological: electrical stimulation, magnetic field treatment, low‐intensity laser treatment, Reiki massage, others) to reduce pain and improve physical function and… 
New Analysis Provides Updated Research Findings on Managing Diabetic Peripheral Nerve Pain
TLDR
A systematic literature review updated the review used to inform the Academy of Neurology’s 2011 guidelines on diabetic peripheral neuropathy as well as findings from an independent 2014 meta-analysis funded by the Mayo Foundation for Medical Education and Research.
Non-pharmacologic treatments for symptoms of diabetic peripheral neuropathy: a systematic review
TLDR
Alpha-lipoic acid and spinal cord stimulation were effective for pain; studies were short-term with quality deficits and further research should address long-term outcomes and other non-pharmacologic treatments.
Pharmacotherapy for diabetic peripheral neuropathy pain and quality of life
TLDR
Quality of life was poorly reported, studies were short-term, drugs had substantial dropout rates, and opioids have significant risks, so future studies should evaluate longer-term outcomes, use methods and measures recommended by pain organizations, and assess patients' quality of life.
Diabetic neuropathic pain: Real World Treatment Options
TLDR
The provider treating PDPN must consider the medication side effects and monitoring parameters, the co-morbid disease states, and the ultimate effects on diabetic control, as well as address patient expectations of treatment.
Suboptimal Treatment of Diabetic Peripheral Neuropathic Pain in the United States.
TLDR
New therapies with improved efficacy and better tolerability are urgently needed for DPNP, as many patients receive lower than recommended dosages, potentially resulting in poor outcomes.
Neuropathic Pain and Pharmacological Treatment
TLDR
A mechanism‐based approach to pharmacological intervention supports the use of polypharmacy in neuropathic pain, which can be relieved but cannot be cured.
An Assessment of Clinically Important Differences on the Worst Pain Severity Item of the Modified Brief Pain Inventory in Patients with Diabetic Peripheral Neuropathic Pain
TLDR
Worst pain on the m-BPI may be used to assess clinically important improvements in DPNP studies, and a high correspondence between observed and predicted PGIC categories at each PGIC threshold was found.
Diabetic Neuropathy: A Position Statement by the American Diabetes Association
TLDR
Although screening for rarer atypical forms of diabetic neuropathy may be warranted, DSPN and autonomic neuropathy are the most common forms encountered in practice and the strongest available evidence regarding treatment pertains to these forms.
Update on the Management of Diabetic Neuropathy
TLDR
Given the high risk of addiction, abuse, psychosocial issues, and mortality, opioids are not recommended as first-, second-, or third-line agents for treating painful DSPN.
Effect of duloxetine on pain, function, and quality of life among patients with chemotherapy-induced painful peripheral neuropathy: a randomized clinical trial.
TLDR
Among patients with painful chemotherapy-induced peripheral neuropathy, the use of duloxetine compared with placebo for 5 weeks resulted in a greater reduction in pain, and the primary hypothesis was that dulOxetine would be more effective than placebo in decreasing chemotherapy- induced peripheral neuropathic pain.
...
...

References

SHOWING 1-10 OF 59 REFERENCES
Gabapentin for the symptomatic treatment of painful neuropathy in patients with diabetes mellitus: a randomized controlled trial.
TLDR
Gabapentin monotherapy appears to be efficacious for the treatment of pain and sleep interference associated with diabetic peripheral neuropathy and exhibits positive effects on mood and quality of life.
Sodium valproate in the management of painful neuropathy in type 2 diabetes - a randomized placebo controlled study.
TLDR
Sodium valproate is a well-tolerated drug and provides significant subjective improvement in painful diabetic neuropathy and provides a basis for future trials of longer duration in a larger group of patients.
Double‐blind randomized trial of tramadol for the treatment of the pain of diabetic neuropathy
TLDR
The results of this placebo-controlled trial showed that tramadol was effective and safe in treating the pain of diabetic neuropathy and no statistically significant treatment effects on sleep were identified.
Diabetic neuropathies: a statement by the American Diabetes Association.
TLDR
Not all patients with peripheral nerve dysfunction have a neuropathy caused by diabetes, and effective symptomatic treatments are available for the manifestations of DPN and autonomic neuropathy.
Sodium valproate for painful diabetic neuropathy: a randomized double-blind placebo-controlled study.
TLDR
Sodium valproate is well-tolerated, and provides significant subjective improvement in painful diabetic neuropathy over 3 months.
...
...